

Resource Summary Report

Generated by [dkNET](#) on Sep 15, 2026

Recombinant Anti-Fibroblast activation protein, alpha antibody [EPR20021]

RRID:AB_2864720

Type: Antibody

Proper Citation

Abcam Cat# ab207178, RRID:AB_2864720

Antibody Information

URL: http://antibodyregistry.org/AB_2864720

Proper Citation: Abcam Cat# ab207178, RRID:AB_2864720

Target Antigen: Fibroblast activation protein, alpha

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P

Antibody Name: Recombinant Anti-Fibroblast activation protein, alpha antibody [EPR20021]

Description: This recombinant targets Fibroblast activation protein, alpha

Target Organism: human

Clone ID: EPR20021

Antibody ID: AB_2864720

Vendor: Abcam

Catalog Number: ab207178

Record Creation Time: 20231110T031959+0000

Record Last Update: 20260830T032315+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Fibroblast activation protein, alpha antibody [EPR20021].

No alerts have been found for Recombinant Anti-Fibroblast activation protein, alpha antibody [EPR20021].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chantzoura E, et al. (2026) The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity. *Cancer immunology research*, 14(2), 243.

Zhu L, et al. (2026) A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. *Cancer discovery*, 16(7), 1360.

Yaghjian L, et al. (2026) Reliability of stromal markers multiplex immunofluorescent staining: pathologist assessment compared to quantitative image analysis. *American journal of cancer research*, 16(5), 1791.

Daum AK, et al. (2025) Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. *Cancer & metabolism*, 13(1), 28.

Al Disi S, et al. (2025) Pharmacological inhibition of hydroxysteroid 11-beta dehydrogenase type 1 (11- β HSD1) after myocardial infarction preserves cardiac function in a translational mini-pig model. *British journal of pharmacology*.

Liu Z, et al. (2025) THBS2-producing matrix CAFs promote colorectal cancer progression and link to poor prognosis via the CD47-MAPK axis. *Cell reports*, 44(4), 115555.

Liu S, et al. (2025) Single-cell and spatial transcriptomic profiling revealed niche interactions sustaining growth of endometriotic lesions. *Cell genomics*, 5(1), 100737.

Jeong MS, et al. (2025) Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. *Cancer letters*, 610, 217339.

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. *Cell reports. Medicine*, 6(9), 102298.

Papadimitriou TI, et al. (2025) CD8+ T cells drive myofibroblast activation and contraction via JAK/STAT3 and TGF β signaling. *iScience*, 28(12), 113904.

Zheng H, et al. (2024) PDGFR β +ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. *Cancer cell*.

Veith I, et al. (2024) Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. *Cell reports. Medicine*, 5(5), 101549.

Niu N, et al. (2024) Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. *Cancer cell*, 42(5), 869.

Hirani P, et al. (2024) Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate. *Cancer research communications*, 4(4), 970.

Rizzoli E, et al. (2024) Fibroblast activation protein is a cellular marker of fibrotic activity in canine idiopathic pulmonary fibrosis. *Frontiers in veterinary science*, 11, 1416124.

Xu GJ, et al. (2023) Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction. *Cell genomics*, 3(10), 100409.

Ji D, et al. (2023) FAP promotes metastasis and chemoresistance via regulating YAP1 and macrophages in mucinous colorectal adenocarcinoma. *iScience*, 26(6), 106600.

Pich-Bavastro C, et al. (2023) Activin A-Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(17), 3498.

Yang X, et al. (2023) Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer. *Cell reports*, 42(10), 113270.

Chu Y, et al. (2023) Establishment and characterization of immortalized human vocal fold fibroblast cell lines. *Biotechnology letters*, 45(3), 347.